Basaglar® KwikPen for Once-Daily Basal Insulin Support

What Basaglar® Is and How It Works

Basaglar® KwikPen is a prefilled, disposable insulin glargine 100 units/mL pen used as a long-acting basal insulin for adults with type 2 diabetes and for adults and pediatric patients with type 1 diabetes. It is injected subcutaneously once daily, at the same time each day. Many people compare Basaglar KwikPen price and features when choosing a basal insulin option.

CanadianInsulin is a prescription referral service. Prescriptions are verified with your clinic, and orders are filled by licensed Canadian pharmacies. We work with licensed and vetted partner pharmacies to supply authentic brand medications with a broad selection and value-focused pricing.

Basaglar provides a steady 24-hour glucose-lowering effect with no pronounced peak. It helps control fasting and between-meal blood sugar and is often paired with mealtime insulin in type 1 diabetes, or with oral agents or GLP-1 therapy in type 2 diabetes. The KwikPen contains 3 mL of insulin (300 units) and doses in 1‑unit increments.

Dosage and Usage

• Typical initiation (type 2 diabetes): 10 units once daily or about 0.2 units/kg once daily, then titrate to fasting glucose targets per prescriber guidance.
• Type 1 diabetes: used as the basal component of a basal–bolus regimen; the basal portion often represents about one‑third to one‑half of total daily insulin, individualized by the care team.
• Titration: adjust by small steps (for example, 2 units every 3–4 days) based on fasting readings, under clinical direction.
• Missed dose: if remembered within the same day, administer the dose and then resume the usual schedule the next day. Leave enough time between doses to reduce hypoglycemia risk. Do not double doses. Contact the clinic for case‑specific guidance.
• Injection sites: abdomen, thigh, upper arm, or buttock. Rotate sites within the same region to reduce lipodystrophy and cutaneous amyloidosis. Avoid scarred, bruised, or inflamed areas.
• KwikPen steps: wash hands. Check the label and confirm the solution is clear and colorless. Attach a new pen needle. Prime the pen until a drop appears. Dial the prescribed dose. Insert the needle subcutaneously and fully depress the plunger. Hold for 10 seconds before removing the needle. Remove the needle and dispose of it in a sharps container. Store the pen with the cap on, without a needle attached.
• Device notes: the Basaglar KwikPen 100 unit/mL delivers in 1‑unit steps and can deliver high single doses (up to the device maximum per injection). Do not share pens or needles.

• Unopened pens: refrigerate at 2–8°C (36–46°F). Do not freeze. Protect from light. Keep in the carton until use.
• In‑use pen: store at room temperature, below 30°C (86°F), for up to 28 days. Do not refrigerate after first use. Keep the cap on and avoid heat and direct sunlight.
• Do not use if frozen, if the solution is cloudy or colored, or if the pen is damaged.
• Travel: carry insulin in an insulated pack with cold packs, avoiding direct contact with ice. Keep medication with you in hand luggage. Bring a prescription copy and supplies (needles, wipes, sharps container).
• Security and temperature: declare diabetes supplies at security checkpoints. If exposure outside the recommended range is suspected, consult a pharmacist before use.

Benefits and Savings

Basaglar offers steady, 24‑hour basal coverage with once‑daily dosing. The KwikPen format is discreet and easy to dial, with clear dose markings and 1‑unit adjustments. Each 3 mL pen contains 300 units, supporting flexible dosing from small to higher daily needs.

Consistent basal insulin can improve fasting glucose and help lower A1C when paired with appropriate nutrition, activity, and adjunct therapies. Many customers save 60–80% vs typical U.S. prices. See our promotions page for current offers, including any basaglar kwikpen manufacturer coupon if available.

Side Effects and Safety

• Common effects: mild hypoglycemia (shakiness, sweating, fast heartbeat, hunger, headache), injection‑site redness or itching, and slight weight gain.
• Less common: lipodystrophy or cutaneous amyloidosis at repeated sites, peripheral edema, or local allergic reactions.
• Hypoglycemia risk increases with missed meals, unplanned activity, alcohol, or dose errors.
• When used with insulin secretagogues (sulfonylureas) or mealtime insulin, hypoglycemia risk is higher and may require dose adjustments.

Serious reactions can include severe hypoglycemia, hypokalemia, generalized hypersensitivity, or fluid retention when combined with thiazolidinediones. Do not use during episodes of hypoglycemia or in patients with known hypersensitivity to insulin glargine or excipients. Do not administer intravenously or intramuscularly, do not use in an insulin pump, and do not mix or dilute with other insulins. Basaglar is not appropriate for diabetic ketoacidosis; use rapid‑acting insulin protocols per clinical guidance.

Onset Time

Glucose‑lowering starts within a few hours after injection. The basal effect is relatively flat over about 24 hours. Steady‑state levels emerge after several days of consistent dosing. Fasting glucose often improves over 1–2 weeks as titration proceeds, while A1C changes typically appear across 8–12 weeks as overall control stabilizes.

Compare With Alternatives

Lantus® (insulin glargine U‑100) offers a similar once‑daily basal profile and is often considered a clinical peer to Basaglar, though the products are not interchangeable without prescriber direction.

Tresiba® (insulin degludec U‑100/U‑200) provides an ultra‑long action (beyond 42 hours) and may allow a more flexible dosing window. Some patients report fewer nocturnal lows, though individual responses vary.

Toujeo® (insulin glargine U‑300) is a more concentrated glargine with a longer, smoother profile that can reduce injection volume for higher daily doses. Device handling, max dose per injection, and titration differ by brand.

Your clinic can help determine whether a glargine option or an ultra‑long alternative best matches prior insulin response, lifestyle, and target fasting ranges.

Combination Therapy

• Basal–bolus: pair Basaglar with rapid‑acting insulin at meals. Adjust prandial doses to carbohydrate intake and readings, under clinical guidance.
• With oral agents: often used with metformin, SGLT2 inhibitors, or DPP‑4 inhibitors to improve overall control.
• With GLP‑1 therapy: agents such as Trulicity®, Ozempic®, or Mounjaro® may reduce required insulin doses and support weight goals.
• To reduce hypoglycemia risk, prescribers may lower mealtime insulin or sulfonylurea doses when basal insulin is initiated or uptitrated.
• Do not mix Basaglar with other insulins in the same syringe and do not use it in pumps.

Patient Suitability and Cost-Saving Tips

Basaglar is indicated for adults with type 2 diabetes who need basal insulin and for adults and children with type 1 diabetes. It may suit individuals seeking once‑daily dosing and a familiar glargine profile. Prescribers consider history of hypoglycemia, renal or hepatic impairment, concomitant medicines, and meal patterns when selecting and titrating basal insulin.

Those with recurrent severe hypoglycemia, true insulin glargine hypersensitivity, or who require IV insulin are not candidates. Basaglar is not for diabetic ketoacidosis. During illness, surgery, pregnancy, or breastfeeding, clinicians may adjust therapy and monitoring plans.

Cost‑saving tips:

• Order multi‑month quantities when appropriate to reduce per‑shipment fees and help avoid gaps.
• Plan refills early; set simple reminders so a Basaglar KwikPen refill arrives before the current pen box runs out.
• Consider pack size needs. Each pen holds 300 units; a 5‑pen box contains 1,500 units.
• Include compatible pen needles in the same shipment to prevent delays.
• Use prompt, express, cold‑chain shipping options to protect medication integrity during transit.

Authoritative Sources

Basaglar (insulin glargine) U.S. Prescribing Information – Eli Lilly

Health Canada Drug Product Database – Basaglar insulin glargine

FDA Label and Medication Guide for Basaglar

Order Basaglar from CanadianInsulin: add to cart, upload your prescription, and we ship with prompt, express, cold‑chain handling.

This page is educational and does not replace medical advice. Always consult a healthcare professional for diagnosis, treatment choices, and personalized dosing.